• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>癌と化学療法 >Management of chemotherapy-induced mucositis and diarrhea
【24h】

Management of chemotherapy-induced mucositis and diarrhea

机译：化疗诱导的粘液炎和腹泻的管理

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Mucositis is a common complication of cytoreductive cancer chemotherapy. Stomatitis is associated with a higher risk of bacterial infection and treatment-related death. Basic oral care is recommended to reduce the incidence and severity of stomatitis. Recently, new effective prophylaxis against stomatitis has been developed such as human keratinocyte growth factor and AES-14. Gastritis can sometimes cause severe bleeding,and it may be life-threatening. It has been shown that prophylactic H2 blockers or proton pump inhibitors can reduce the incidence and severity of gastric mucosal injury. The risk for chemotherapy-induced diarrhea is significantly greater for chemotherapeutic regimens that contain irinotecan. Intestinal alkalization and Hangeshasin-to a Chinese herbal product are applied in clinical practice in Japan to prevent or reduce irinotecan-induced diarrhea,but careful monitoring,early detection and rapid cure are most important to prevent treatment-related death.
机译：粘膜炎是细胞功能性癌症化疗的常见并发症。 口腔炎与细菌感染和治疗相关死亡的风险更高。 建议基本口腔护理减少口腔炎的发病率和严重程度。 最近，已经开发出对口腔炎的新有效预防，例如人类角质形成细胞生长因子和AES-14。 胃炎有时会导致严重出血，并且可能是危及生命的。 已经表明，预防性H2阻滞剂或质子泵抑制剂可以降低胃粘膜损伤的发生率和严重程度。 化学疗法诱导的腹泻风险对于含有伊替康的化学治疗方案显着更大。 肠道碱化和梭菌对中草产物适用于日本的临床实践中，以防止或减少伊替康诱导的腹泻，但仔细监测，早期检测和快速治愈最重要的是预防治疗有关的死亡。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号